{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "R-synuclein",
        "Protein_Change": {
          "ref": "A",
          "alt": "P",
          "position": "30"
        },
        "variant_string_id": "R-synuclein A30P"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "The protein R-synuclein is the major protein component of Lewy bodies (LWB), the morphological hallmark of Parkinson's disease (PD). Mutations A30P, A53T, and E46K are linked to the familial early onset of PD.",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines the disease mechanism relevant to the functional assay, linking R-synuclein mutations to PD."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The study used isothermal titration calorimetry (ITC) to study the thermodynamics of binding of Cu(II) to WT R-synuclein and two mutants, A53T and A30P, at near-physiological conditions.",
          "judgment": "Yes",
          "reasoning": "The general class of assay (ITC) effectively models the disease pathogenesis by examining Cu(II) binding, which is implicated in PD pathogenesis.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "extracted_paper_info": "The study included basic controls (wild-type protein and two mutants) and performed multiple replicates (two runs for each condition with deviations within 10%).",
          "judgment": "Yes",
          "reasoning": "Basic controls and replicates were adequately described, meeting the criteria for validity.",
          "next_step_or_outcome": "Proceed to Sub-step 3c"
        },
        {
          "step_name": "Sub-step 3c: Variant Controls",
          "extracted_paper_info": "The study compared the binding of Cu(II) to wild-type protein and two separate single mutation proteins (A30P and A53T) associated with familial Parkinson's diseases.",
          "judgment": "Yes",
          "reasoning": "Variant controls (known pathogenic variants) were used, enhancing the assay's validity.",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "extracted_paper_info": "The study provided binding constants and stoichiometry under near-physiological conditions, showing that A30P exhibits two binding constants, with the major binding site having slightly lower affinity than WT or A53T.",
          "judgment": "No",
          "reasoning": "No statistical analyses sufficient to estimate or calculate OddsPath were provided.",
          "next_step_or_outcome": "Proceed to Sub-step 4b"
        },
        {
          "step_name": "Sub-step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The study used two variant controls (A30P and A53T) in addition to the wild-type protein.",
          "judgment": "No",
          "reasoning": "The total number of benign/pathogenic variant controls used across the study was less than 11.",
          "next_step_or_outcome": "Max PS3_supporting / Max BS3_supporting"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The A30P variant in R-synuclein was assessed for its functional evidence in the context of Parkinson's disease. The study provided adequate controls and replicates but lacked sufficient statistical analysis for OddsPath calculation. The evidence strength is supporting (PS3_supporting) due to the use of variant controls and the demonstration of altered Cu(II) binding properties compared to wild-type."
    },
    {
      "variant_id": {
        "Gene": "R-synuclein",
        "Protein_Change": {
          "ref": "A",
          "alt": "T",
          "position": "53"
        },
        "variant_string_id": "R-synuclein A53T"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "The protein R-synuclein is the major protein component of Lewy bodies (LWB), the morphological hallmark of Parkinson's disease (PD). Mutations A30P, A53T, and E46K are linked to the familial early onset of PD.",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines the disease mechanism relevant to the functional assay, linking R-synuclein mutations to PD."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The study used isothermal titration calorimetry (ITC) to study the thermodynamics of binding of Cu(II) to WT R-synuclein and two mutants, A53T and A30P, at near-physiological conditions.",
          "judgment": "Yes",
          "reasoning": "The general class of assay (ITC) effectively models the disease pathogenesis by examining Cu(II) binding, which is implicated in PD pathogenesis.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "extracted_paper_info": "The study included basic controls (wild-type protein and two mutants) and performed multiple replicates (two runs for each condition with deviations within 10%).",
          "judgment": "Yes",
          "reasoning": "Basic controls and replicates were adequately described, meeting the criteria for validity.",
          "next_step_or_outcome": "Proceed to Sub-step 3c"
        },
        {
          "step_name": "Sub-step 3c: Variant Controls",
          "extracted_paper_info": "The study compared the binding of Cu(II) to wild-type protein and two separate single mutation proteins (A30P and A53T) associated with familial Parkinson's diseases.",
          "judgment": "Yes",
          "reasoning": "Variant controls (known pathogenic variants) were used, enhancing the assay's validity.",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "extracted_paper_info": "The study provided binding constants and stoichiometry under near-physiological conditions, showing that A53T binds Cu(II) similarly to WT.",
          "judgment": "No",
          "reasoning": "No statistical analyses sufficient to estimate or calculate OddsPath were provided.",
          "next_step_or_outcome": "Proceed to Sub-step 4b"
        },
        {
          "step_name": "Sub-step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The study used two variant controls (A30P and A53T) in addition to the wild-type protein.",
          "judgment": "No",
          "reasoning": "The total number of benign/pathogenic variant controls used across the study was less than 11.",
          "next_step_or_outcome": "Max PS3_supporting / Max BS3_supporting"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The A53T variant in R-synuclein was assessed for its functional evidence in the context of Parkinson's disease. The study provided adequate controls and replicates but lacked sufficient statistical analysis for OddsPath calculation. The evidence strength is supporting (PS3_supporting) due to the use of variant controls and the demonstration of similar Cu(II) binding properties to wild-type."
    }
  ]
}